Immunosuppression and infection in transplant recipients

被引:3
作者
Martin-Davila, Pilar
Blanes, Marino
Fortun, Jesus
机构
[1] Hosp Ramon & Cajal, Serv Enfermedades Infecciosas, E-28034 Madrid, Spain
[2] Hosp Fe, Unidad Enfermedades Infecciosas, Valencia, Spain
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2007年 / 25卷 / 02期
关键词
immunosuppression; transplant; opportunistic infection;
D O I
10.1016/S0213-005X(07)74244-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Recognizing a foreign element is an inherent characteristic of living beings and guarantees their survival. Evading this defense mechanism is one of the most difficult requirements for transplant success, but it leads to a series of consequences, mainly related to infection. T lymphocytes are the cornerstone of the allogenic response. These cells recognize intracellular and extracellular antigens over HLA molecules in host cells. As a consequence, lymphocytic expansion occurring on several levels is produced, and a humoral or cellular response is the final result. The immunosuppression regimens used in transplantation include induction, maintenance and rescue therapy. Induction therapy serves primarily to decrease the proportion of T-cell precursors and to lower the efficacy of antigen presentation. With respect to maintenance therapy, cyclosporine and tacrolimus inhibit cytokine transcription, azathioprine, and mycophenolate mofetil inhibit nucleotide synthesis, and sirolimus and everolimus inhibit transduction of growth factor signals. As a consequence of immunosuppression, opportunistic microorganisms may appear with endogenic reactivation of latent infection or from an exogenous origin. Prevention of these infections by proper knowledge of the risk factors, rapid diagnosis, and adequate management are fundamental to guarantee the survival of the patient.
引用
收藏
页码:143 / 154
页数:12
相关论文
共 57 条
[1]   Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain [J].
Aguado, JM ;
Herrero, JA ;
Gavalda, J ;
TorreCisneros, J ;
Blanes, M ;
Rufi, G ;
Moreno, A ;
Gurgui, M ;
Hayek, M ;
Lumbreras, C ;
Morales, JM ;
Pahissa, A ;
Margerit, C ;
Prada, JL ;
Kindelan, JM ;
Ros, F ;
Pallardo, LM ;
Carratala, J ;
Gudiol, F ;
Gonzalez, J ;
Vilardell, J ;
Guirado, L ;
Rabella, N .
TRANSPLANTATION, 1997, 63 (09) :1278-1286
[2]  
[Anonymous], 2004, Am J Transplant, V4 Suppl 10, P66
[3]   Antigen processing and presentation in transplantation [J].
Auchincloss, H ;
Sultan, H .
CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (05) :681-687
[4]   Managing the highly sensitized transplant recipient and B cell tolerance [J].
Baid, S ;
Saidman, SL ;
Tolkoff-Rubin, N ;
Williams, WW ;
Delmonico, FL ;
Cosimi, AB ;
Pascual, M .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (05) :577-581
[5]   Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation [J].
Barth, Rolf N. ;
Janus, Christina A. ;
Lillesand, Christine A. ;
Radke, Nancy A. ;
Pirsch, John D. ;
Becker, Bryan N. ;
Fernandez, Luis A. ;
Chin, L. Thomas ;
Becker, Yolanda T. ;
Odorico, Jon S. ;
D'Alessandro, Anthony M. ;
Sollinger, Hans W. ;
Knechtle, Stuart J. .
TRANSPLANT INTERNATIONAL, 2006, 19 (11) :885-892
[6]   HCV-related fibrosis progression following liver transplantation:: increase in recent years [J].
Berenguer, M ;
Ferrell, L ;
Watson, J ;
Prieto, M ;
Kim, M ;
Rayón, M ;
Córdoba, J ;
Herola, A ;
Ascher, N ;
Mir, J ;
Berenguer, J ;
Wright, TL .
JOURNAL OF HEPATOLOGY, 2000, 32 (04) :673-684
[7]   Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression [J].
Bernabeu-Wittel, M ;
Naranjo, M ;
Cisneros, JM ;
Cañas, E ;
Gentil, MA ;
Algarra, G ;
Pereira, P ;
González-Roncero, FJ ;
de Alarcón, A ;
Pachón, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (03) :173-180
[8]   Activation and function of natural killer cell responses during viral infections [J].
Biron, CA .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (01) :24-34
[9]   Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: A large randomized clinical study [J].
Boillot, O ;
Mayer, DA ;
Boudjema, K ;
Salizzoni, M ;
Gridelli, B ;
Filipponi, F ;
Trunecka, P ;
Krawczyk, M ;
Clavien, PA ;
Ducerf, C ;
Margarit, C ;
Margreiter, R ;
Pallardo, JM ;
Hoeckerstedt, K ;
Pageaux, GP .
LIVER TRANSPLANTATION, 2005, 11 (01) :61-67
[10]   A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients [J].
Charpentier, B ;
Rostaing, L ;
Berthoux, F ;
Lang, P ;
Civati, G ;
Touraine, JL ;
Squifflet, JP ;
Vialtel, P ;
Abramowicz, D ;
Mourad, G ;
Wolf, P ;
Cassuto, E ;
Moulin, B ;
Rifle, G ;
Pruna, A ;
Merville, P ;
Mignon, F ;
Legendre, C ;
Le Pogamp, P ;
Lebranchu, Y ;
Toupance, O ;
de Ligny, BH ;
Touchard, G ;
Olmer, M ;
Purgus, R ;
Pouteil-Noble, C ;
Glotz, D ;
Bourbigot, B ;
Leski, M ;
Wauters, JP ;
Kessler, M .
TRANSPLANTATION, 2003, 75 (06) :844-851